Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; its reference list is not available; 24 of the 129 sources its claims cite were checked for support.

Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment

Open access
Godlewska, Beata R., Harmer, Catherine J. · 2021 · Psychopharmacology

Abstract

Depression is a leading cause of disability worldwide and improving its treatment is a core research priority for future programmes. A change in the view of psychological and biological processes, from seeing them as separate to complementing one another, has introduced new perspectives on pathological mechanisms of depression and treatment mode of action. This review presents a theoretical model that incorporated this novel approach, the cognitive neuropsychological hypothesis of antidepressant action. This model proposes that antidepressant treatments decrease the negative bias in the processing of emotionally salient information early in the course of antidepressant treatment, which leads to the clinically significant mood improvement later in treatment. The paper discusses the role of negative affective biases in the development of depression and response to antidepressant treatments. It also discusses whether the model can be applied to other antidepressant interventions and its potential translational value, including treatment choice, prediction of response and drug development.

Overview

CoChat Summary

TL;DR

The paper reviews the cognitive neuropsychological hypothesis of antidepressant action, which proposes that antidepressants first reduce negative bias in emotional processing and that this early shift, combined with social-environment interactions, later produces mood improvement. It surveys behavioral, neuroimaging, animal, and treatment studies supporting the model and discusses its translational potential and unresolved gaps.

Key findings

  • The model addresses the delayed clinical effect of conventional antidepressants: biological effects occur within hours, but symptomatic improvement is rarely seen before 1 week, with clear and sustained effects often not evident until 4–6 weeks.
  • Short-term antidepressant treatment in healthy volunteers and depressed patients shifts emotional processing at behavioral and neural levels; for example, 7 days of escitalopram differentiated 6-week responders from non-responders across regions including left amygdala, insula, anterior and posterior cingulate, supramarginal gyri, and thalamus, while placebo-controlled fMRI showed normalization of amygdala responsiveness without mood differences.
  • Early emotional-processing measures predicted later response: Browning et al. (2019) reported 77% accuracy in a training sample of 74 primary care patients and 60% in an independent sample of 239; Shiroma et al. (2014) found that 7-day citalopram-related happy-face recognition predicted remission at 56 days in 27 older depressed adults only when perceived social support was adequate.
  • Translational implications include treatment personalization and drug development; memantine and aprepitant failed to affect emotional processing and lacked antidepressant efficacy, while rimonabant reduced positive bias and was associated with depressive symptoms and suicidal ideation.

Methods

  • Narrative review and theoretical synthesis of the cognitive neuropsychological hypothesis; no new primary data are reported.
  • Synthesizes human behavioral and fMRI/PET studies, healthy-volunteer and depressed-patient samples, animal models, and trials or studies of pharmacological, ECT, TMS/tDCS, DBS, CBT, and cognitive bias modification interventions.
  • Main analysis is qualitative integration of cited evidence, including selected quantitative results from cited studies such as prediction accuracies and sample sizes.

Limitations

  • Stated in the paper: the early emotional-processing shift is not yet ready for wider clinical use; more work is needed to improve prediction accuracy and differentiate drug classes or individual medications; the social-interaction component requires further testing; the timeline and which emotion’s processing modification is crucial remain unclear; ketamine/glutamatergic applications need validation; and early emotional-processing shift during CBT has not yet been explored in depression.
  • Evident from the text: as a narrative review, conclusions depend on cited studies with heterogeneous designs, doses, samples, and measures, and no systematic search or meta-analytic synthesis is reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00213-019-05448-0

Cites

Statistics

Nothing to recompute.

Figures

Fig. 1 Schematic presentation of the cognitive neuropsychological model of antidepressant action. ‘Classical’ antidepressant drugs (ADs) (i.e. the ones that take weeks to induce mood change, such as selective serotonin reuptake inhibitors, SSRIs, or selective serotonin reuptake inhibitors, SNRIs, significantly improve mood only after a few weeks of treatment, despite biological changes taking place already in the first few hours after the first dose is applied, and continuing thereafter. The model proposes that for these early biological effects to be translated into clinical improvement, two key processes need to happen. The first one is a positive shift in the processing of emotionally salient information. Such a shift has been shown to occur at behavioural and neural level as early as after a single antidepressant dose. Subsequently, this new more positive bias needs to be ‘enacted’ by interactions with the social environment, which leads to the development of new positive associations in the learning associated processes. This happens in the context of continued downstream biological and neuroadaptive processes, for which repeated administration of ADs is needed. This is a lengthy process and explains the delay in the symptomatic improvement.
Fig. 1 Schematic presentation of the cognitive neuropsychological model of antidepressant action. ‘Classical’ antidepressant drugs (ADs) (i.e. the ones that take weeks to induce mood change, such as selective serotonin reuptake inhibitors, SSRIs, or selective serotonin reuptake inhibitors, SNRIs, significantly improve mood only after a few weeks of treatment, despite biological changes taking place already in the first few hours after the first dose is applied, and continuing thereafter. The model proposes that for these early biological effects to be translated into clinical improvement, two key processes need to happen. The first one is a positive shift in the processing of emotionally salient information. Such a shift has been shown to occur at behavioural and neural level as early as after a single antidepressant dose. Subsequently, this new more positive bias needs to be ‘enacted’ by interactions with the social environment, which leads to the development of new positive associations in the learning associated processes. This happens in the context of continued downstream biological and neuroadaptive processes, for which repeated administration of ADs is needed. This is a lengthy process and explains the delay in the symptomatic improvement.CC BY · PubMed Central
Fig. 2 The hypothetical place of rapid acting ADs within the cognitive neuropsychological model of antidepressant action. Rapid-acting ADs, such as ketamine, were hypothesised to reduce or abolish memory for already existing negative associations. This, contrary to learning new positive ones, is a fast process, resulting in faster but more transient effect on mood. More research is needed to validate this hypothesis.
Fig. 2 The hypothetical place of rapid acting ADs within the cognitive neuropsychological model of antidepressant action. Rapid-acting ADs, such as ketamine, were hypothesised to reduce or abolish memory for already existing negative associations. This, contrary to learning new positive ones, is a fast process, resulting in faster but more transient effect on mood. More research is needed to validate this hypothesis.CC BY · PubMed Central
Fig. 3 A schematic representation of changes in brain activity over an acute (one dose) or short-term (7–10 days) treatment with an antidepressant medication. Brain regions in which such changes were identified are listed in corresponding colour-coded boxes. Emotions, which processing in these regions has changed over treatment, and studies that showed these changes, are listed. Most of the studies used a variation of emotional faces processing task, the minority—self-referential processing task. Medications were applied orally unless otherwise indicated
Fig. 3 A schematic representation of changes in brain activity over an acute (one dose) or short-term (7–10 days) treatment with an antidepressant medication. Brain regions in which such changes were identified are listed in corresponding colour-coded boxes. Emotions, which processing in these regions has changed over treatment, and studies that showed these changes, are listed. Most of the studies used a variation of emotional faces processing task, the minority—self-referential processing task. Medications were applied orally unless otherwise indicatedCC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 2 Not valid · 64 Not checked · 33 Own results and interpretations

69 more claims · 11 with their cited sources checked

Create a free account to see all 119 claims and to verify the 105 references still open.

See all claims — free account
  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 119 · Cited by 123

Research works printed but not linked: 1

  1. Robinson ES, Roiser JP (2016) Affective biases in humans and animals. Curr Top Behav Neurosci 28:263–286 · DOI · Paper page

Metadata

Authors
Godlewska, B. R., & Harmer, C. J.
Affiliations
  • Warneford Hospital (GB)
  • Oxford Health NHS Foundation Trust (GB)
Corresponding author
Godlewska, Beata R.
Venue
Psychopharmacology
Published
2020-01-15
Volume
238
Issue
5
Pages
1265-1278
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W2999837842
Cited by
123
References
119
Citations by year
2026: 15 · 2025: 18 · 2024: 20 · 2023: 21 · 2022: 26 · 2021: 16 · 2020: 6
FWCI
2.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
University of Oxford
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
depression, antidepressant action, mood improvement, treatment response prediction, antidepressant drug development, treatment selection, translational psychiatry
MeSH terms
Affect, Antidepressive Agents, Cognition, Depression, Emotions, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. https://app.cochat.ai/papers/10.1007/s00213-019-05448-0
The paper
Godlewska, B. R., & Harmer, C. J. (2021). Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. Psychopharmacology. https://doi.org/10.1007/s00213-019-05448-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.